Yesterday was supposed to be my chemotherapy day.I went to the hospital as usual, thinking, "The day of treatment is here ...

After progressing from a complete hydatidiform mole to an invasive mole,and finishing two surgeries,I started chemotherapy ...

A study in mice and human tissue suggests psilocybin protects against peripheral neuropathy, a common side effect of chemotherapy. The findings are so promising that researchers are starting a mid-sta ...

Approximately a third of patients with breast cancer reported increased fatigue 2 years after receiving chemotherapy, but addressing any depression and/or stress may significantly reduce this lethargy ...

The same drugs powerful enough to kill cancer cells can also damage healthy tissue. UC Irvine researchers are trying to ...

Addition of a “simple” clinical risk score on top of current risk assessment tools may improve identification of patients ...

Both the clinical effects and the unpleasant side effects of chemotherapies, from hair loss to mouth sores to gastrointestinal discomfort, stem from their indiscriminate destruction of cells prone to ...

The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk ...

Amivantamab plus chemotherapy demonstrates durable benefit with a differentiated approach that dual targets EGFR and MET1Median overall survival reached 34.3 months with the amivantamab-based regimen, ...

'Instead of thinking of it as poison or toxic, think of it as healing.' ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting adverse effect of platinum-based chemotherapies that features pain and sensory deficits in the periphery.